AxoGen, Inc. (AXGN)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$38.06+3.76%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge AxoGen, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+2.1%

+10% or more+5%0%−5%−10% or less

0.68 → 0.70 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	79.39M
EPS	—	0.126
FY 2026 · Annual
Revenue	—	283.76M
EPS	—	0.455
Gross margin	At least 73%	—
Revenue growth	At least 20%	—
FY 2027 · Annual
Revenue	—	360.62M
EPS	—	0.699

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve free cash flow positivity in 2026	A primary condition in AxoGen, Inc.'s published investment case. The stated target is free cash flow positive.	Improving	free cash flow remains negative through FY26	Cash from operations: $1.494M FY2026-Q2; GAAP. Published target: free cash flow positive. Target period is not explicitly aligned with this observation. Source published Jul 29, 20261,494,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain gross margin between 74% and 76% in 2026	Gross margin should stay between 74% and 76%.	Under Pressure	gross margin falls below 70% in FY26	Gross margin: 72.67% FY2026-Q2; GAAP. Published target: 74% to 76% gross margin. Target period is not explicitly aligned with this observation. Source published Jul 29, 202672.670692 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 49a51ddd-98da-412d-ae44-15b27b76c26c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve at least 20% revenue growth in 2026	A primary condition in AxoGen, Inc.'s published investment case. The stated target is >=20% YoY revenue growth.	Intact	YoY revenue growth falls below 15% in FY26	Revenue growth: 23.06% FY2026-Q2; GAAP. Published target: >=20% YoY revenue growth. Target period is not explicitly aligned with this observation. Source published Jul 29, 202623.064841 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 49a51ddd-98da-412d-ae44-15b27b76c26c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $61.5 million in 2026-Q1 to $69.7 million in 2026-Q2. Management raised full-year revenue guidance from at least $270 million to $279 million, targeting at least 24% growth. The trajectory is delivering consistent growth aligned with stated guidance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.70

$0.73 → $0.70 · observed estimates

FY2027 revenue$0.36B

$0.32B → $0.36B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.73	$318,414,560	6 / 9
2026-07-25	$0.73	$318,414,560	6 / 9
2026-07-26	$0.73	$318,414,560	6 / 9
2026-07-27	$0.73	$318,414,560	6 / 9
2026-07-28	$0.73	$318,414,560	6 / 9
2026-07-29	$0.73	$318,447,890	6 / 9
2026-07-30	$0.73	$318,447,890	6 / 9
2026-07-31	$0.68	$331,169,110	7 / 9
2026-08-01	$0.68	$331,169,110	7 / 9
2026-08-02	$0.68	$331,169,110	7 / 9
2026-08-03	$0.68	$331,169,110	7 / 9
2026-08-04	$0.68	$331,169,110	7 / 9
2026-08-05	$0.68	$331,169,110	7 / 9
2026-08-06	$0.68	$331,169,110	7 / 9
2026-08-07	$0.68	$331,169,111	5 / 7
2026-08-08	$0.69	$330,258,000	7 / 9
2026-08-09	$0.69	$330,258,000	7 / 9
2026-08-10	$0.69	$330,258,000	7 / 9
2026-08-11	$0.69	$330,258,000	7 / 9
2026-08-12	$0.69	$330,258,000	7 / 9
2026-08-13	$0.69	$330,258,000	7 / 9
2026-08-14	$0.68	$331,169,111	5 / 7
2026-08-15	$0.68	$331,169,111	5 / 7
2026-08-16	$0.68	$331,169,111	5 / 7
2026-08-17	$0.68	$331,169,111	5 / 7
2026-08-18	$0.68	$331,169,111	5 / 7
2026-08-19	$0.68	$331,169,111	5 / 7
2026-08-20	$0.68	$331,169,111	5 / 7
2026-08-21	Unavailable	$331,169,111	4 / 7
2026-08-22	Unavailable	$331,169,111	4 / 7
2026-08-23	Unavailable	$331,169,111	4 / 7
2026-08-24	Unavailable	$331,169,111	4 / 7
2026-08-25	Unavailable	$331,166,667	4 / 7
2026-08-26	Unavailable	$331,166,667	4 / 7
2026-08-27	Unavailable	$331,166,667	4 / 7
2026-08-28	Unavailable	$331,166,667	4 / 7
2026-08-29	$0.69	$331,879,800	5 / 7
2026-08-30	$0.69	$331,879,800	5 / 7
2026-08-31	$0.69	$331,879,800	5 / 7
2026-09-01	$0.69	$331,879,800	5 / 7
2026-09-02	$0.69	$331,879,800	5 / 7
2026-09-03	$0.69	$331,879,800	5 / 7
2026-09-04	$0.69	$331,879,800	5 / 7
2026-09-05	$0.69	$331,879,800	5 / 7
2026-09-06	$0.69	$331,879,800	5 / 7
2026-09-07	$0.69	$331,879,800	5 / 7
2026-09-08	$0.69	$331,879,800	5 / 7
2026-09-09	$0.69	$331,879,800	5 / 7
2026-09-10	$0.69	$331,879,800	5 / 7
2026-09-11	$0.69	$331,879,800	5 / 7
2026-09-12	$0.69	$335,632,000	5 / 7
2026-09-13	$0.69	$335,632,000	5 / 7
2026-09-14	$0.69	$335,632,000	5 / 7
2026-09-15	$0.69	$335,632,000	5 / 7
2026-09-16	$0.68	$335,631,400	5 / 7
2026-09-17	$0.68	$335,631,400	5 / 7
2026-09-18	$0.68	$335,631,400	5 / 7
2026-09-19	$0.68	$335,631,400	5 / 7
2026-09-20	$0.68	$335,631,400	5 / 7
2026-09-21	$0.68	$335,631,400	5 / 7
2026-09-22	$0.68	$335,631,400	5 / 7
2026-09-23	$0.68	$335,631,400	5 / 7
2026-09-24	$0.68	$335,631,400	5 / 7
2026-09-25	$0.68	$335,631,400	5 / 7
2026-09-26	$0.69	$339,941,400	5 / 7
2026-09-27	$0.69	$339,941,400	5 / 7
2026-09-28	$0.69	$339,941,400	5 / 7
2026-09-29	$0.69	$339,941,400	5 / 7
2026-09-30	$0.69	$339,941,400	5 / 7
2026-10-01	$0.69	$339,941,400	5 / 7
2026-10-02	$0.69	$339,941,400	5 / 7
2026-10-03	$0.69	$350,104,740	5 / 7
2026-10-04	Unavailable	$350,104,700	4 / 7
2026-10-05	$0.69	$350,104,700	5 / 7
2026-10-06	$0.69	$350,104,700	5 / 7
2026-10-07	Unavailable	$353,504,700	3 / 5
2026-10-08	Unavailable	$353,504,700	4 / 5
2026-10-09	Unavailable	$353,504,700	4 / 5
2026-10-10	Unavailable	$353,504,700	4 / 5
2026-10-11	Unavailable	$356,834,700	4 / 5
2026-10-12	Unavailable	$356,834,700	4 / 5
2026-10-13	Unavailable	$357,836,989	4 / 5
2026-10-14	$0.68	$357,839,916	5 / 6
2026-10-15	$0.68	$357,839,916	5 / 6
2026-10-16	$0.68	$357,839,916	5 / 6
2026-10-17	$0.68	$357,839,916	5 / 6
2026-10-18	$0.68	$357,839,916	5 / 6
2026-10-19	$0.69	$360,623,908	5 / 6
2026-10-20	$0.69	$360,623,908	5 / 6
2026-10-21	$0.69	$360,623,908	5 / 6
2026-10-22	$0.69	$360,623,908	5 / 6
2026-10-23	$0.69	$360,623,908	5 / 6
2026-10-24	$0.70	$360,623,908	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	0	0
2026-06-01	9	0	0
2026-07-01	9	0	0
2026-08-01	10	0	0
2026-09-01	10	0	0
2026-10-01	12	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 23 · prior Oct 6

$55.00 → $50.00-9.1%

Truist FinancialOct 1 · prior Aug 26

$60.00 → $53.00-11.7%

Raymond JamesSep 25 · prior Apr 29

$48.00 → $53.00+10.4%

$0$33.00$66.00

1 raises · 2 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve free cash flow positivity in 2026Cash from operations: $1.494M
Maintain gross margin between 74% and 76% in 2026Published status: Under Pressure
Achieve at least 20% revenue growth in 2026Revenue growth: 23.06%

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-33.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

AxoGen, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

AXGN is a growth-focused medical-device business with elevated risk, rather than a proven profitable compounder. Its multi-year thesis is intact, but confidence is medium because earnings quality remains loss-making and management execution is mixed.

What's priced into AxoGen, Inc.

AXGN carries a durable premium versus peers, and the valuation tag says that premium is justified. The expectations gap is negative, suggesting expectations may be ahead of what the evidence supports, though valuation-model confidence is low.

What the fundamentals likely do

Near-term results show revenue rising from the first to the second quarter, and management raised its 2026 revenue guidance to at least 24% growth. Gross margin slipped just below management’s 73% goal, while positive free cash flow remains an annual goal with limited second-quarter data; the company also missed its most recent quarter and has a history of a deep miss.

What AxoGen, Inc. hinges on

The multi-year thesis depends on sustaining revenue growth while restoring gross margin to at least 73% and achieving positive free cash flow in 2026. Near term, a guidance cut would be a meaningful setback, while weakening employment data could increase recession concerns; continued strength from healthcare bellwethers would support the sector backdrop.